Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

467

HTML

6269

Figures (1-4)

259

Tables (1-2)

153

Sum=7148

Nov 7, 2011 (publication date) through Apr 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Nov 7, 2011; 17(41): 4563-4571
Published online Nov 7, 2011. doi: 10.3748/wjg.v17.i41.4563

Table 2 Survival of hepatocellular carcinoma patients with different alpha fetoprotein levels over two years

Time (mo)	Survival rates (%) (dead/alive cases)
	< 20 μg/L	20-250 μg/L	≥ 250 μg/L
0	100.0 (0/68)	100.0 (0/36)	100.0 (0/56)
6	95.7 (3/65)	97.2 (1/35)	91.1 (5/51)
12	94.1 (4/64)	97.2 (1/35)	80.4 (11/45)
18	91.2 (6/62)	91.7 (3/33)	73.2 (15/41)
24	86.8 (9/59)	88.9 (4/32)	69.6 (17/39)^a

^aP < 0.05 vs serum alpha fetoprotein < 20 μg/L and 20-250 μg/L groups.

Citation: Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 2011; 17(41): 4563-4571
URL: https://www.wjgnet.com/1007-9327/full/v17/i41/4563.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i41.4563